Mipomersen, an apolipoprotein b synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial

Journal of the American College of Cardiology

Volumn 62, Issue 23, 2013, Pages 2178-2184

  Thomas, Gregory S ^a,b   Cromwell, William C ^c   Ali, Shariq ^d   Chin, Wai ^d   Flaim, Joann D ^e   Davidson, Michael ^f  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Lipoprotein and Metabolic Disorders Institute   (United States)

^d GENZYME CORPORATION   (United States)

^e ISIS PHARMACEUTICALS   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

antisense oligonucleotides; apolipoprotein B; cholesterol inhibitors; hypolipidemic agents; lipid regulating agents

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NITROGEN; PLACEBO; TRIACYLGLYCEROL; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FATTY LIVER; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LIPOPROTEIN SYNTHESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

EID: 84888090979     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.081     Document Type: Article

References (19)

1. L. Nielsen Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis Atherosclerosis 123 1996 1 15
2. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
3. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 229
4. L. Grigore, G.D. Norata, and A.L. Catapano Combination therapy in cholesterol reduction: focus on ezetimibe and statins Vasc Health Risk Manag 4 2008 267 268
5. A. Tavridou, G. Ragia, and V.G. Manolopoulos Emerging targets for the treatment of dyslipidemia Curr Med Chem 18 2011 909 912
6. D.N. Ricotta, and W. Frishman Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia Cardiol Rev 20 2012 90 95
7. J.J. Kastelein, M.K. Wedel, and B.F. Baker Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B Circulation 114 2006 1729 1735
8. F.J. Raal, R.D. Santos, and D.J. Blom Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
9. E.A. Stein, R. Dufor, and C. Gagne Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
10. M. McGowan, J.C. Tardif, and R. Ceska Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS ONE 7 2012 e49006
11. S.M. Grundy, J.I. Cleeman, and S.R. Daniels American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
12. J.M. McKenney, P.H. Jones, and H.E. Bays Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study) Atherosclerosis 192 2007 432 437
13. W. Cromwell, R. Dufour, and C. Gagne Mipomersen, an apolipoprotein B synthesis inhibitor, reduces small LDL particle number and increases LDL particle size in patients with heterozygous familial hypercholesterolemia and coronary artery disease Circulation 122 2010 A19931
14. W.C. Cromwell, R.D. Santos, and D.J. Blom Mipomersen, an apoB synthesis inhibitor, preferentially reduces small LDL particle number and increases LDL particle size in HoFH patients Atheroscler Suppl 11 2010 107 108
15. R.G. Lee, W. Fu, and M.J. Graham Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein J Lipid Res 54 2013 602 614
16. P.B. Duell, R.D. Santos, and C. East Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia uncontrolled by maximally tolerated lipid lowering therapy J Clin Lipidol 6 2012 291
17. M.E. Visser, G. Wagener, and B.F. Baker Mipomersen, an apolipoprotein B synthesis inhibitor, lowers LDL cholesterol in high risk-statin intolerant patients: a randomized, double-blind, placebo-controlled trial Eur Heart J 33 2012 1142 1149
18. A. Amaro, E. Fabbrini, and M. Kars Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia Gastroenterol 139 2010 149 153
19. M.E. Visser, N.M. Lammers, and A.J. Nederveen Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia Diabetologia 54 2011 2113 2121